Send to

Choose Destination
Cell Transplant. 2000 May;9(3):307-317. doi: 10.1177/096368970000900302.

In Vivo Persistence of Donor Cells following Adoptive Transfer of Allogeneic Dendritic Cells in HIV-Infected Patients.

Author information

Dendreon Corporation, Seattle, WA 98121.
Center for AIDS Research, Stanford University Medical Center, Stanford, CA 94305.
Stanford Medical School Blood Center, Stanford, CA 94034.


Peripheral blood samples from HIV-seropositive individuals enrolled in a pilot clinical trial investigating the use of allogeneic dendritic cell therapy were evaluated for mixed chimerism. In this study, dendritic cells from HLA-identical, HIV-seronegative siblings were used. Patients received an infusion of dendritic cells pulsed with HIV MN gp160 protein or with peptides from HLA-A2 restricted epitopes of env, gag, and pol proteins every month for 6-9 months. Of the five allogeneic dendritic cell recipients, two showed increases in HIV antigen-specific immune responses. Allele-specific polymorphisms were identified in three sib-pairs that allowed infused donor cells to be detected using sensitive PCR-based molecular methods. Analysis of blood samples from patients showed similar patterns of donor cell persistence after the first infusion, in that cells were detectable for at least 1 week. Also, differences were observed in the kinetics of cell survival between the first and subsequent infusion cycles in all three patients. This suggests variation in HIV-specific immune responses detected among these three patients was not due to differences in persistence of infused donor cells.


Allele-specific polymorphism; Cell survival; Dendritic cells; Mixed chimerism


LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center